Patterns and Prevalence of Metabolic Syndrome Among Psychiatric Inpatients Receiving Antipsychotic Medications: Implications for the Practicing Psychologist

Professional Psychology: Research and Practice

Volumn 41, Issue 3, 2010, Pages 244-252

  Bisconer, Sarah W ^a   Harte, Brittany M B ^a  

^a The College of William and Mary

Author keywords

antipsychotics; metabolic syndrome; schizophrenia; treatment.

Indexed keywords

EID: 77953833028     PISSN: 07357028     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0018981     Document Type: Article

References (33)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders-IV (1994), Author, Washington, DC
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders-IV-TR (2000), Author, Washington, DC
4. Aquila R., and Emanuel M. Interventions for weight gain in adults treated with novel antipsychotics. Journal of Clinical Psychiatry 2 (2000) 20-23
5. Ball M.P., Coons V.B., and Buchanan R.W. A program for treating olanzapine-related weight gain. Psychiatric Services 52 (2001) 967-969
6. Bishara D., and Taylor D. Upcoming agents for the treatment of schizophrenia: Mechanisms of action, efficacy and tolerability. Drugs 68 (2008) 2269-2292
7. Cruess D.G., Schneiderman N., Antoni M.H., and Penedo F. Biobehavioral bases of disease processes. In: Boll T.J., Raczynski J.M., and Leviton L.C. (Eds). Handbook of Clinical Health Psychology: Disorders of Behavior and Health 2 (2004), APA, Washington, D.C.
8. Diabetes Prevention Program. DPP lifestyle change program: DPP lifestyle materials for sessions 1-16 - Standard participant handouts (1996). http://www.bsc.gwu.edu/dpp/lifestyle/dpp_part.html Retrieved from http://www.bsc.gwu.edu/dpp/lifestyle/dpp_part.html
9. Eli Lilly and Company. Solutions for wellness: My fitness and nutrition program (2007). http://www.solutionsforwellness.info/ Retrieved from http://www.solutionsforwellness.info/
10. Everson S.A., Goldberg D.E., Helmrich S.P., Lakka T.A., Lynch J.W., Kaplan G.A., and Salonen J.T. Weight gain and the risk of developing insulin resistance syndromes. Diabetes Care 21 (1998) 1637-1643
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association 285 (2001) 2486-2497
12. Farberman R.K. Council in action. Monitor on Psychology 40 (2009) 76-77
13. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-Mental State: A practical method for grading the state of patients for the clinician. Journal of Psychiatric Research 12 (1975) 189-198
14. Gravetter F.J., and Wallnau L.B. Essentials of statistics for the behavioral sciences. 6th ed. (2008), Thomson Wadsworth, Belmont, CA
15. Green A., Patel J., Goisman R., Allison D., and Blackburn G. Weight gain from novel antipsychotic drugs: Need for action. General Hospital Psychiatry 22 (2000) 224-235
16. Kapur S., and Remington G. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annual Review of Medicine 52 (2001) 503-517
17. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry 156 (1999) 286-293
18. Kuroki T., Nagao N., and Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: A validity of the serotonin-dopamine hypothesis. Progress in Brain Research 172 (2008) 199-212
19. Lieberman J.A., Stroup S.T., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 353 (2005) 1209-1223
20. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., and Shon S. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161 (2004) 1334-1349
21. Martin S. Embrace the future. Monitor on Psychology 40 (2009) 74-75
22. Martin S. Roadmap for change. Monitor on Psychology 40 (2009) 66-67
23. Meltzer H.Y., and Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Progress in Brain Research 172 (2008) 177-197
24. Menza J., Vreeland B., Minsky S., Gara M., Radler D.R., and Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. Journal of Clinical Psychiatry 65 (2004) 471-477
25. Meyer J., Koro C.E., and L'Italien G.J. The metabolic syndrome and schizophrenia: A review. International Review of Psychiatry 17 (2005) 173-180
26. National Institute of Mental Health. Schizophrenia (2005). http://www.nimh.nih.gov/publicat/schizoph.cfm Retrieved from http://www.nimh.nih.gov/publicat/schizoph.cfm
27. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychological Reports 10 (1962) 799-812
28. Poulin J.J., Chaput J.P., Simard V., Vincent P., Bernier J., Gauthier Y., and Tremblay A. Management of antipsychotic-induced weight gain: Prospective naturalistic study of the effectiveness of a supervised exercise programme. Australian and New Zealand Journal of Psychiatry 41 (2007) 980-989
29. Rosenheck R.A., Leslie D.L., Sindelar J., Miller E.A., Lin H., Stroup T.S., and Lieberman J. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American Journal of Psychiatry 163 (2006) 2080-2089
30. Smith West D., Harvey-Berino J., and Raczynski J.M. Behavioral aspects of obesity, dietary intake, and chronic disease. In: Boll T.J., Raczynski J.M., and Leviton L.C. (Eds). Handbook of clinical health psychology: Disorders of behavior and health 2 (2004), APA, Washington, D.C. 9-41
31. Stroup S.T., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., and Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia trial design and protocol development. Schizophrenia Bulletin 29 (2003) 15-31
32. Weber M., and Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophrenia Research 83 (2006) 95-101
33. Worrel J.A., Marken P.A., Beckman S.B., and Ruehter V. Atypical antipsychotic agents: A critical review. American Journal of Health Systems and Pharmacology 52 (2000) 238-255